Medication info

Hanapephrine Hydrochloride Injection 1%

Prescription medicationIntramuscular injection · Intravenous injection · Subcutaneous injection
Ingredient · strength
Phenylephrine Hydrochloride›10mg / 1mL
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
A colorless and transparent liquid in a brown vial injection
Packaging
1mL x 10 vials
Approval status
Active

MFDS item code 199702362 · Notified 1997.02.26 · Insurance code 657802731

Summary

Main use
Improvement of blood pressure and circulatory disorders (hypotension, shock, etc.); prolongation of anesthesia; treatment of supraventricular tachycardia
Who receives it
Adults · Children
Adult administration
Generally, administer by subcutaneous injection, intramuscular injection, slow intravenous injection, or continuous direct intravenous infusion as a diluted solution. In patients with paroxysmal supraventricular tachycardia and emergency patients, administer by direct intravenous injection if directed by a physician. The dose should be adjusted according to the blood pressure response. For convenience during intermittent intravenous injection, dilute 1 milliliter of phenylephrine hydrochloride 1% injection with 9 milliliters of water for injection to make a 0.1% solution. 1. Moderate hypotension Subcutaneous or intramuscular injection: The usual dose is 2-5mg, administered within a range of 1-10mg. The initial dose should not exceed 5mg. Intravenous injection: The usual dose is 0.2mg, administered within a range of 0.1-0.5mg. The initial dose should not exceed 0.5mg. When repeated, the dose should not be administered again within 10-15 minutes. An intramuscular dose of 5mg raises blood pressure for 1-2 hours. An intravenous dose of 0.5mg raises blood pressure for approximately 15 minutes. 2. Severe hypotension and shock-including drug-induced hypotension In patients with persistent or poorly treated severe hypotension or shock, appropriately increase the initial and maintenance doses of this drug. Infusion: Dilute 10mg of phenylephrine hydrochloride (1ml of a 1% solution) in 500ml of glucose injection or saline injection (a 1:50,000 solution). To raise blood pressure rapidly, use an initial rate of 100-180mcg/min (100-180 drops/min, based on 20 drops/ml). Once blood pressure has stabilized, a maintenance rate of 40-60mcg/min (40-60 drops/min, based on 20 drops/ml) is sufficient. Adjust the rate according to the number of drops per ml if the dropper size differs. If a rapid initial response does not occur, add more phenylephrine (10mg or more) to the infusion bottle. Then adjust the infusion rate until the desired blood pressure is reached. 3. Spinal anesthesia-hypotension Parenteral use of phenylephrine is generally recommended for the prevention and treatment of hypotension during spinal anesthesia. It is recommended to administer by subcutaneous or intramuscular injection 3-4 minutes before the spinal anesthetic injection. The total dose usually required is 3mg for high spinal anesthesia and 2mg for low spinal anesthesia. In an emergency involving hypotension during spinal anesthesia, administer phenylephrine intravenously, with an initial dose of 0.2mg. Each additional dose should not exceed the previous dose by more than 0.1-0.2mg. A single dose should not exceed 0.5 milligrams. 4. Prolongation of spinal anesthesia Adding 2-5 milligrams of phenylephrine hydrochloride to the anesthetic solution can increase the duration of motor blockade by approximately 50%, without causing complications such as nausea, vomiting, or blood pressure imbalance. 5. Vasoconstrictor for local anesthesia When used as a vasoconstrictor, a concentration approximately 10 times that of epinephrine is recommended. The optimal concentration is 1:20.000 (prepared by adding 1 milligram of phenylephrine hydrochloride to every 20 milliliters of local anesthetic solution.) A pressor response may occur with injection of 2 milligrams or more. 6. Paroxysmal supraventricular tachycardia Rapid intravenous injection (within 20-30 seconds) is required. The initial dose should not exceed 0.5 milligrams; additional doses should be determined according to the initial blood pressure response, should not exceed the previous dose by more than 0.1-0.2 milligrams, and should not exceed 1 milligram.
Child administration
To overcome hypotension during spinal anesthesia in children, administration of 0.5-1 milligrams/25 pounds (11.34 kilograms) based on body weight by subcutaneous or intramuscular injection is recommended.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood pressure and circulatory disorders (hypotension, shock, etc.); prolongation of anesthesia; treatment of supraventricular tachycardia

  • Blood pressure regulation during anesthesia
  • shock
  • shock-like conditions
  • drug-induced hypotension
  • vascular instability during hypersensitivity reactions
  • paroxysmal supraventricular tachycardia
View approved original text

This medication is used to adequately control blood pressure during anesthesia. It helps maintain appropriate blood pressure levels during spinal or inhalation anesthesia, and treats issues related to shock states or hypotension caused by medications and hypersensitivity reactions through vascular constriction. It is also effective in treating paroxysmal supraventricular tachycardia. Additionally, it prolongs the duration of spinal anesthesia and constricts blood vessels during regional anesthesia. Thus, it is effective in stabilizing blood pressure and blood vessels in various situations.

How it is given

Adult administration

Generally, administer by subcutaneous injection, intramuscular injection, slow intravenous injection, or continuous direct intravenous infusion as a diluted solution. In patients with paroxysmal supraventricular tachycardia and emergency patients, administer by direct intravenous injection if directed by a physician. The dose should be adjusted according to the blood pressure response. For convenience during intermittent intravenous injection, dilute 1 milliliter of phenylephrine hydrochloride 1% injection with 9 milliliters of water for injection to make a 0.1% solution. 1. Moderate hypotension Subcutaneous or intramuscular injection: The usual dose is 2-5mg, administered within a range of 1-10mg. The initial dose should not exceed 5mg. Intravenous injection: The usual dose is 0.2mg, administered within a range of 0.1-0.5mg. The initial dose should not exceed 0.5mg. When repeated, the dose should not be administered again within 10-15 minutes. An intramuscular dose of 5mg raises blood pressure for 1-2 hours. An intravenous dose of 0.5mg raises blood pressure for approximately 15 minutes. 2. Severe hypotension and shock-including drug-induced hypotension In patients with persistent or poorly treated severe hypotension or shock, appropriately increase the initial and maintenance doses of this drug. Infusion: Dilute 10mg of phenylephrine hydrochloride (1ml of a 1% solution) in 500ml of glucose injection or saline injection (a 1:50,000 solution). To raise blood pressure rapidly, use an initial rate of 100-180mcg/min (100-180 drops/min, based on 20 drops/ml). Once blood pressure has stabilized, a maintenance rate of 40-60mcg/min (40-60 drops/min, based on 20 drops/ml) is sufficient. Adjust the rate according to the number of drops per ml if the dropper size differs. If a rapid initial response does not occur, add more phenylephrine (10mg or more) to the infusion bottle. Then adjust the infusion rate until the desired blood pressure is reached. 3. Spinal anesthesia-hypotension Parenteral use of phenylephrine is generally recommended for the prevention and treatment of hypotension during spinal anesthesia. It is recommended to administer by subcutaneous or intramuscular injection 3-4 minutes before the spinal anesthetic injection. The total dose usually required is 3mg for high spinal anesthesia and 2mg for low spinal anesthesia. In an emergency involving hypotension during spinal anesthesia, administer phenylephrine intravenously, with an initial dose of 0.2mg. Each additional dose should not exceed the previous dose by more than 0.1-0.2mg. A single dose should not exceed 0.5 milligrams. 4. Prolongation of spinal anesthesia Adding 2-5 milligrams of phenylephrine hydrochloride to the anesthetic solution can increase the duration of motor blockade by approximately 50%, without causing complications such as nausea, vomiting, or blood pressure imbalance. 5. Vasoconstrictor for local anesthesia When used as a vasoconstrictor, a concentration approximately 10 times that of epinephrine is recommended. The optimal concentration is 1:20.000 (prepared by adding 1 milligram of phenylephrine hydrochloride to every 20 milliliters of local anesthetic solution.) A pressor response may occur with injection of 2 milligrams or more. 6. Paroxysmal supraventricular tachycardia Rapid intravenous injection (within 20-30 seconds) is required. The initial dose should not exceed 0.5 milligrams; additional doses should be determined according to the initial blood pressure response, should not exceed the previous dose by more than 0.1-0.2 milligrams, and should not exceed 1 milligram.

Child administration

To overcome hypotension during spinal anesthesia in children, administration of 0.5-1 milligrams/25 pounds (11.34 kilograms) based on body weight by subcutaneous or intramuscular injection is recommended.

Precautions

This medication stimulates the sympathetic nervous system to elevate blood pressure. It may cause serious side effects, such as severe hypertension or cerebral vascular rupture, if used in conjunction with drugs that induce uterine contractions. Individuals allergic to sulfites may experience severe allergic reactions or asthma symptoms due to the components contained in this medication, so caution is advised. Patients with hypertension or rapid heart rate, as well as those with known allergies to this drug, should not use it. Elderly patients, those with hyperthyroidism, those with bradycardia or conduction problems, and individuals with heart disease or severe atherosclerosis should use this drug cautiously. Users should monitor for symptoms such as headache, bradycardia, anxiety or agitation, and occasionally arrhythmias while using the drug. When used with other antihypertensives or certain antidepressants, there is an increased risk of cardiac side effects, so caution is necessary. It is advisable not to use this medication during pregnancy unless absolutely necessary, and adequate studies on its effects on the fetus have not been conducted. Discretion is required when used by nursing mothers and children, following medical advice. In case of overdose, symptoms may include cardiac rhythm disturbances, headache, and peripheral pain, and immediate treatment is necessary if blood pressure rises excessively. Before use, check externally to confirm that the drug has not been discolored or contaminated and store it in a sealed container protected from light, maintaining a temperature between 15 to 30 degrees Celsius.

Side effects

  • Headache
  • reflex bradycardia
  • agitation
  • anxiety
  • arrhythmia
  • ventricular ectopic beats
  • transient ventricular tachycardia
  • heaviness in the head
  • pain in the limbs

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that blocks out light, and it is important to maintain a storage temperature between 15 and 30 degrees Celsius. This way of storage helps in retaining the drug's effectiveness and preventing degradation.

Appearance and packaging

Appearance

A colorless and transparent liquid in a brown vial injection

Package unit

1mL x 10 vials

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.